Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,708.60
Bid: 1,708.40
Ask: 1,708.80
Change: 3.40 (0.20%)
Spread: 0.40 (0.023%)
Open: 1,701.60
High: 1,713.00
Low: 1,699.40
Prev. Close: 1,705.20
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-China launches crackdown on pharmaceutical sector

Wed, 17th Jul 2013 08:15

By Megha Rajagopalan

BEIJING, July 17 (Reuters) - China announced a nationwidecrackdown on the sale of illegal medicine on Wednesday and saidit would tighten industry regulation, piling pressure on asector already reeling from a bribery scandal at Britishdrugmaker GlaxoSmithKline.

The State Food and Drug Administration said the six-monthcampaign would also target illegal online drug sales and thesale of fake traditional Chinese medicine. It gave no details onpossible changes to regulation.

"We must resolutely punish illegal acts, expose illegalenterprises, recall problematic products," Wu Zhen, the agency'sdeputy commissioner, said in a statement.

The crackdown comes two days after Chinese police accusedGlaxoSmithKline of bribing officials and doctors to boost salesand raise the price of its medicines in China.

Police said GSK transferred up to 3 billion yuan ($489million) to 700 travel agencies and consultancies over six yearsto facilitate the bribes. In response, GSK said it was deeplyconcerned by the developments, which it called "shameful".

The food and drug agency did not specifically mention GSK,but a spokesman for China's Commerce Ministry said authoritieswould not hold back punishing companies engaged in bribery.

"Whether it's a domestic or foreign-invested enterprise,once it has violated Chinese law, it will be sanctioned," ShenDanyang told a news conference.

Widespread counterfeit drugs and false advertising have beena thorn in the side of Chinese regulators for years, and thedrug agency has conducted campaigns in the past to crack down.

The issue infuriates Chinese consumers, who also expressanger at what they see as the high price of legitimate medicine.

A commentary in the People's Daily newspaper said China must"lift a sharp sword to pierce the improper, even illegal, costsbehind rising drug prices" for which multinationals, such asGSK, were responsible.

China's planning agency, the National Development and ReformCommission (NDRC), is examining prices charged by 60 local andinternational drugmakers including units of GSK, Merck & Co Inc and Astellas Pharma Inc.

The pharmaceutical sector was a "disaster zone", said WillyLam, adjunct professor of history at the Chinese University ofHong Kong.

"This seems to be the largest and the best orchestratedeffort to target multinationals ... they seem to be blamingforeigners for problems they cannot solve themselves," said Lam,who closely follows corruption issues in China.

Underscoring the heat on foreign companies, a separatecommentary in the People's Daily called for a crackdown oncommercial bribery by multinational firms in general.

It accused some of using their market dominance to exploitgaps in regulatory systems in developing countries.

"A crackdown on commercial bribery by multinationals isdeeply significant to safeguarding the order of the marketeconomy and protecting an environment of fair competition," saidthe commentary in the mouthpiece of the ruling Communist Party.

Project bidding and tax systems for multinationals were alsoproblematic, the commentary said, without giving details.

FOCUS ON FOREIGN FIRMS

Some experts have suggested China may be expanding ananti-corruption drive beyond government ranks and domesticcompanies including state-run entities, focusing now on foreignfirms.

China has targeted foreign firms on multiple fronts in thepast few months, although the probe into GSK is the onlyhigh-profile, publicly known investigation focused on bribery.

European food companies Nestle and Danone said early this month they would cut infant milkformula prices in China after Beijing launched an investigationinto the industry.

Chinese media has been giving the GSK story plenty ofattention.

On Tuesday night, state broadcaster CCTV night aired aninterview with one of four detained Chinese executives from GSK.

Liang Hong, vice president and operations manager of GSK(China) Investment Co Ltd, offered details on how he funnelledmoney through travel agencies by arranging conferences, some ofwhich were never held.

"To have contact with some government departments you needmoney that you cannot normally expense to the company," Liangsaid during the broadcast.

Liang said he paid bribes to officials from the NDRC as wellas the Ministry of Labour and Social Security, which are amongthose required to get medicines approved or prices set.

It is rare for state TV to carry such interviews, althoughstate news agency Xinhua had earlier been given access to Liang.

More News
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.